Intraocular Melanoma Completed Phase 2 Trials for Thalidomide (DB01041)

Also known as: Intraocular melanoma NOS

IndicationStatusPhase
DBCOND0028574 (Intraocular Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00072345Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaTreatment
NCT00238329PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic MelanomaTreatment